RE: going up20 Dec 2022 13:50
Just to remind everyone - as Nolupus reminded me yesterday.....
Talk of share price is only relevant when 'in context' and when you also consider the number of shares in total.
So, back in June '19, before Lanstead received 27m 'new shares' the price was 13p - most of which they got at 10p discounted value, so you could even argue 10p is the new 'diluted value'.
Total shares was 139,467,430 @13.3p = £1.8m MCAP
Today the total shares is 333,403,115 @1.62p = £5.4m MCAP
Based on the fact that there are almost 2.5x more shares now that at 13p, a same value for the company (£1.8m) would put the share price at 0.54p, so the 1.62p we see today actually represents a 300% gain in the value of the company in a little over 3 years. Meaning 'dilution' (as always in AIM stocks) is the reason retail investors are in loss.
So any talk of a return to 7p would need a significant change (share burn / major breakthrough) as this would set the company on a valuation of over £23m (or over 12x what is was worth in June '19).
Just for clarity - yes - I have somewhat increased my holdings to bring down my average price, which no doubt I will reduce on the next positive news in order to return some of that additional investment. However, I still believe IMM can make a major advance, not just in Lupus trials but in its many other avenues, so I will be retaining the majority of my stake for the years ahead.